India Glycols Fixes Sept 1 Effective Date & Sept 2 Record Date for Scheme of Arrangement
India Glycols Limited has set September 1, 2026, as the Effective Date and September 2, 2026, as the Record Date for its Scheme of Arrangement. Shareholders will receive shares in Ennature Bio Pharma and IG L Spirits based on specified ratios.
The scheme of arrangement and subsequent share allotment/listing can have a significant impact on the company's structure and shareholder value, warranting a medium impact rating.
The announcement is a procedural update regarding a scheme of arrangement and does not inherently contain positive or negative financial information.
India Glycols Limited has announced the fixation of the Effective Date and Record Date for the allotment of shares pursuant to a Scheme of Arrangement. The Board of Directors, through a resolution passed by circulation on 21st August 2026, has set Tuesday, 1st September 2026, as the Effective Date. This date signifies the filing of the NCLT's sanctioned order with the Registrar of Companies.
Furthermore, Wednesday, 2nd September 2026, has been designated as the Record Date. This date will be used to determine the eligible shareholders for the allotment of shares in two Resulting Companies: Ennature Bio Pharma Limited (EBL) and IG L Spirits Limited (IGSL).
Under the scheme, shareholders of India Glycols Limited (the Demerged Company) will receive shares in the Resulting Companies based on specific ratios. For every 3 Equity Shares of ₹5 face value held in India Glycols, shareholders will receive 1 Equity Share of ₹5 face value in EBL. Additionally, for every 1 Equity Share of ₹5 face value held in India Glycols, shareholders will receive 1 Equity Share of ₹5 face value in IGSL. The equity shares to be allotted by the Resulting Companies will be listed on the National Stock Exchange of India Limited and BSE Limited, subject to regulatory approvals.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under restructuring. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.